US · AIFC · SOFTWARE - INFRASTRUCTURE
AI Financial Corporation (AIFC) intrinsic value and stock valuation
$0.51as of 2026-09-18 · Mkt cap 68.97M
Data updated · price as of 2026-09-18
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
AI Financial Corporation DCF and intrinsic value
InvestorsCraft values AIFC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AIFC’s statements →
AI Financial Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2025–2021, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| FY | FY | FY | FY | FY | |
|---|---|---|---|---|---|
| Revenue | $24.8T | $11.9T | $0.00 | $0.00 | $40T |
| Operating income | -$-22.85T | -$-6.92T | -$-19.85T | -$-3.15T | -$-3.22T |
| Net income | -$-344.51T | -$-7.57T | -$-7.81T | $11T | -$-16.89T |
| EPSd | -$-5.91M | -$-675.81K | -$-1.76M | $3.49M | -$-6.35M |
| Operating cash flow | -$-7.16T | — | — | — | — |
| Capital expenditure | -$-718.73T | — | — | — | — |
| Free cash flow | -$-725.89T | — | — | — | — |
| Total assets | $1,219.5T | — | — | — | — |
| Total debt | $15.4T | — | — | — | — |
| Net debt | $9.14T | — | — | — | — |
| Total equity | $1,155.3T | — | — | — | — |
| Cash and short-term investments | $6.22T | — | — | — | — |
Income statement
| FY | FY | FY | FY | FY | |
|---|---|---|---|---|---|
| Revenue | $24.8T | $11.9T | $0.00 | $0.00 | $40T |
| Cost of revenue | $14.7T | $6.24T | $0.00 | $0.00 | $31.2T |
| Gross profit | $10.2T | $5.65T | $0.00 | $0.00 | $8.87T |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $33T | $12.6T | $4.75T | $3.15T | $12.1T |
| Other expenses | $0.00 | $0.00 | $15.1T | $0.00 | $0.00 |
| Operating expenses | $33T | $12.6T | $19.8T | $3.15T | $12.1T |
| Cost and expenses | $47.7T | $18.8T | $19.8T | $3.15T | $43.2T |
| Interest income | $0.00 | $0.00 | $2.25T | $468B | $0.00 |
| Interest expense | $0.00 | $879B | $0.00 | $489B | $773B |
| Depreciation and amortization | $3.39T | $1.35T | $1.45T | $2B | $448B |
| Ebitda | -$-19.46T | -$-5.58T | -$-3.29T | -$-3.15T | -$-2.77T |
| Operating income | -$-22.85T | -$-6.92T | -$-19.85T | -$-3.15T | -$-3.22T |
| Total other income/expenses, net | -$-405.38T | -$-1.54T | $2.32T | $4.55T | $180B |
| Income before tax | -$-428.23T | -$-8.46T | -$-17.52T | $1.4T | -$-3.04T |
| Income tax expense | -$-86.74T | -$-160B | -$-429B | -$-6.62T | $273B |
| Net income | -$-344.51T | -$-7.57T | -$-7.81T | $11T | -$-16.89T |
| Weighted average shares outstanding | $58.3T | $11.2T | $4.01T | $3.15T | $13.5T |
| Weighted average diluted shares outstanding | $58.3T | $11.2T | $4.44T | $3.15T | $2.66T |
Balance sheet
| FY | |
|---|---|
| Cash and short-term investments | $6.22T |
| Net receivables | $20.3T |
| Inventory | $0.00 |
| Total current assets | $29.5T |
| Property, plant and equipment, net | $130B |
| Goodwill and intangible assets | $35.3T |
| Long-term investments | $0.00 |
| Total non-current assets | $1,190T |
| Total assets | $1,219.5T |
| Accounts payable | $5.1T |
| Short-term debt | $6.51T |
| Deferred revenue | $1.2T |
| Total current liabilities | $51.4T |
| Long-term debt | $8.85T |
| Deferred revenue, non-current | $0.00 |
| Total non-current liabilities | $12.7T |
| Capital lease obligations | $112B |
| Total liabilities | $64.1T |
| Common stock | $126B |
| Retained earnings | -$-402.71T |
| Accumulated other comprehensive income (loss) | -$-6.31T |
| Total equity | $1,155.3T |
| Total investments | $0.00 |
| Total debt | $15.4T |
| Net debt | $9.14T |
Cash flow statement
| FY | |
|---|---|
| Net income | -$-341.49T |
| Depreciation and amortization | $3.39T |
| Stock-based compensation | $5.9T |
| Change in working capital | $9.84T |
| Accounts receivable | $4.83T |
| Inventory | $0.00 |
| Accounts payable | -$-2.23T |
| Net cash provided by operating activities | -$-7.16T |
| Investments in property, plant and equipment | -$-11B |
| Acquisitions, net | $122B |
| Net cash used for investing activities | -$-706.61T |
| Common stock issued | $0.00 |
| Common stock repurchased | $0.00 |
| Dividends paid | $0.00 |
| Net cash used for financing activities | $716.8T |
| Net change in cash | -$-955B |
| Cash at end of period | $6.22T |
| Operating cash flow | -$-7.16T |
| Capital expenditure | -$-718.73T |
| Free cash flow | -$-725.89T |
Line items
Line items
Line items
About AI Financial Corporation
AI Financial Corporation, a global entity operating through its various subsidiaries, specializes in distributed ledger technology solutions. The company's activities are strategically divided into two primary segments: Fintech and Biotechnology. Its Fintech division manages the entire ecosystem of digital assets, covering everything from their initial creation (tokenization) to their trading, clearing, settlement, payment processing, and secure safekeeping. Within this sector, AI Financial offers significant products such as ALT 5 Prime, a sophisticated electronic over-the-counter (OTC) trading platform designed for the acquisition and divestiture of digital assets. Another key offering is ALT 5 Pay, a cryptocurrency payment gateway that empowers merchants to either accept and disburse payments in digital currencies directly or integrate this capability into their existing software applications. The biotechnology arm is dedicated to identifying, procuring, licensing, advancing, collaborating on, and commercializing innovative, non-opioid, and non-addictive therapeutic solutions for addressing pain and addiction. Noteworthy projects include JAN 101, an orally administered, sustained-release sodium nitrite compound that has successfully concluded Phase 2a clinical trials for the treatment of peripheral arterial disease and pain. Additionally, the company is developing JAN123, a low-dose naltrexone formulation specifically tailored for managing chronic regional pain syndrome. Established in 1976, the company is based in Las Vegas, Nevada. It officially adopted its current name, AI Financial Corporation, in April 2026, having previously been known as ALT5 Sigma Corporation.
- CEO
- Antonios Isaac
- Employees
- 16
- Beta
- 1.85
Explore
Frequently asked questions
What is the intrinsic value of AI Financial Corporation (AIFC)?
InvestorsCraft does not currently publish an intrinsic value for AIFC. How the IC value is calculated.
Is AIFC undervalued?
InvestorsCraft does not publish an undervaluation signal for AIFC at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.